Actively Recruiting

Phase Not Applicable
Age: 18Years - 65Years
All Genders
NCT06993922

Dexmedetomidine as an Adjuvant to Bupivacaine in Scalp Block Versus Bupivacaine Alone for Postoperative Pain Management in Patients Undergoing Craniotomy

Led by Ain Shams University · Updated on 2025-05-30

50

Participants Needed

1

Research Sites

22 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study aims to compare dexmedetomidine as an adjuvant to bupivacaine in scalp block versus bupivacaine alone for postoperative pain management in patients undergoing craniotomy.

CONDITIONS

Official Title

Dexmedetomidine as an Adjuvant to Bupivacaine in Scalp Block Versus Bupivacaine Alone for Postoperative Pain Management in Patients Undergoing Craniotomy

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age from 18 to 65 years.
  • Both sexes.
  • American Society of Anesthesiologists (ASA) physical status I or II.
  • Undergoing supratentorial elective planned craniotomies.
Not Eligible

You will not qualify if you...

  • Patient refusal.
  • Known allergy to the local anesthetic or dexmedetomidine.
  • Bleeding disorders.
  • Local infection at the injection site.
  • Emergency craniotomy.
  • Psychotic disorder.
  • Patients not extubated in the operating room after surgery.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Ain Shams University

Cairo, Egypt, 11591

Actively Recruiting

Loading map...

Research Team

O

Omar A Khiralla, MBBCH

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here